{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:43:57Z","timestamp":1792197837461,"version":"4.4.0"},"reference-count":36,"publisher":"The Pediatric Pharmacy Association","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"abstract":"<jats:p>Late-onset sepsis in neonates can lead to significant morbidity and mortality, especially in preterm infants. Vancomycin is commonly prescribed for the treatment of Gram-positive organisms, particularly methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA), coagulase-negative staphylococci, and ampicillin-resistant <jats:italic>Enterococcus<\/jats:italic> species in adult and pediatric patients. Currently, there is no consensus on optimal dosing and monitoring of vancomycin in neonates. Different vancomycin dosing regimens exist for neonates, but with many of these regimens, obtaining therapeutic trough concentrations can be difficult. In 2011, the Infectious Diseases Society of America recommended vancomycin trough concentrations of 15 to 20 mg\/L or an AUC\/MIC ratio of \u2265400 for severe invasive diseases (e.g., MRSA) in adult and pediatric patients. Owing to recent reports of increased risk of nephrotoxicity associated with vancomycin trough concentrations of 15 to 20 mg\/L and AUC\/MIC of \u2265400, a revised consensus guideline, recently published in 2020, no longer recommends monitoring vancomycin trough concentrations in adult patients. The guideline recommends an AUC\/MIC of 400 to 600, which has been found to achieve clinical efficacy while reducing nephrotoxicity. However, these recommendations were derived solely from adult literature, as there are limited clinical outcomes data in pediatric and neonatal patients. Furthermore, owing to the variation of vancomycin pharmacokinetic parameters among the neonatal population, these recommendations for achieving vancomycin AUC\/MIC of 400 to 600 in neonates require further investigation. This review will discuss the challenges of achieving optimal vancomycin dosing and monitoring in neonatal patients.<\/jats:p>","DOI":"10.5863\/1551-6776-25.6.476","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T15:06:28Z","timestamp":1597417588000},"page":"476-484","source":"Crossref","is-referenced-by-count":14,"title":["Challenges of Vancomycin Dosing and Therapeutic Monitoring in Neonates"],"prefix":"10.5863","volume":"25","author":[{"given":"Jennifer T.","family":"Pham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"issue":"suppl 2","key":"i1551-6776-25-6-476-b1","series-title":"Early Hum Dev","first-page":"S69","article-title":"Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units","volume":"88","year":"2012","unstructured":"Hornik\n              CP\n            , FortP, ClarkRH, \n          et al. Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units. Early Hum Dev. 2012;88(suppl 2):S69\u2013S74."},{"issue":"2","key":"i1551-6776-25-6-476-b2","series-title":"Pediatrics","doi-asserted-by":"publisher","first-page":"e20191881","DOI":"10.1542\/peds.2019-2350","article-title":"Management of infants at risk for group B streptococcal disease","volume":"144","year":"2019","unstructured":"Puopolo\n              KM\n            , LynfieldR, CummingsJJ, Committee on Fetus and Newborn; Committee on Infectious Diseases.\n          Management of infants at risk for group B streptococcal disease. Pediatrics. 2019;144(2):e20191881. doi:10.1542\/peds.2019-2350"},{"issue":"3","key":"i1551-6776-25-6-476-b3","series-title":"Pediatr Infect Dis J","first-page":"238","article-title":"Risk for late-onset blood-culture proven sepsis in very-low-birth weight infants born small for gestational age: a large multicenter study from the German Neonatal Network","volume":"33","year":"2014","unstructured":"Tr\u00f6ger\n              B\n            , G\u00f6pelW, FaustK, \n          et al. Risk for late-onset blood-culture proven sepsis in very-low-birth weight infants born small for gestational age: a large multicenter study from the German Neonatal Network. Pediatr Infect Dis J. 2014;33(3):238\u2013243."},{"issue":"1","key":"i1551-6776-25-6-476-b4","series-title":"Pediatr Infect Dis J","first-page":"e7","article-title":"Incidence, clinical characteristics, and risk factors for adverse outcome in neonates with late onset sepsis","volume":"33","year":"2014","unstructured":"Tsai\n              MH\n            , HsuJF, ChuSM, \n          et al. Incidence, clinical characteristics, and risk factors for adverse outcome in neonates with late onset sepsis. Pediatr Infect Dis J. 2014;33(1):e7\u2013e13."},{"key":"i1551-6776-25-6-476-b5","series-title":"Performance Standards for Antimicrobial Susceptibility Testing.","year":"2006","unstructured":"Clinical and Laboratory Standards Institute\n          .Performance Standards for Antimicrobial Susceptibility Testing.Wayne, PA: Clinical and Laboratory Standards Institute; 2006. CLSI-approved standard M100-s16."},{"issue":"8","key":"i1551-6776-25-6-476-b6","series-title":"Eur J Clin Microbiol Infect Dis","first-page":"1503","article-title":"Factors impacting unbound vancomycin concentrations in neonates and young infants","volume":"37","year":"2018","unstructured":"Smits\n              A\n            , PauwelsS, OyaertM, \n          et al. Factors impacting unbound vancomycin concentrations in neonates and young infants. Eur J Clin Microbiol Infect Dis. 2018;37(8):1503\u20131510."},{"key":"i1551-6776-25-6-476-b7","series-title":"Neofax 2011","year":"2011","unstructured":"Thomas Reuters Clinical Editorial Staff\n          .Neofax 2011. 24th ed. PDR Network; 2011."},{"key":"i1551-6776-25-6-476-b8","series-title":"Red Book 2018: Report of the. Committee on Infectious Diseases","year":"2018","unstructured":"Kimberlin\n              DW\n            , LongSS, BradyMT, JacksonMA.\n          Red Book 2018: Report of the. Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018."},{"issue":"5","key":"i1551-6776-25-6-476-b9","series-title":"Pediatr Res","first-page":"696","article-title":"Serum creatinine concentration in very-low-birth-weight infants from birth to 34\u201336 wk postmenstrual age","volume":"77","year":"2015","unstructured":"Bateman\n              DA\n            , ThomasW, ParraviciniE, \n          et al. Serum creatinine concentration in very-low-birth-weight infants from birth to 34\u201336 wk postmenstrual age. Pediatr Res. 2015;77(5):696\u2013702."},{"key":"i1551-6776-25-6-476-b10","series-title":"Pediatric and Neonatal Dosage Handbook","year":"2016","unstructured":"Taketomo\n              CK\n            , HoddingJH, KrausDM.\n          Pediatric and Neonatal Dosage Handbook. 23rd ed. Hudson, OH: Lexicomp; 2016."},{"issue":"6","key":"i1551-6776-25-6-476-b11","series-title":"Ther Drug Monit","first-page":"756","article-title":"Evaluation of vancomycin use in late-onset neonatal sepsis using the area under the concentration-time curve to the minimum inhibitory concentration \u2265 400 target","volume":"37","year":"2015","unstructured":"Bhongsatiern\n              J\n            , StockmannC, RobertsJK, \n          et al. Evaluation of vancomycin use in late-onset neonatal sepsis using the area under the concentration-time curve to the minimum inhibitory concentration \u2265 400 target. Ther Drug Monit. 2015;37(6):756\u20137865."},{"issue":"3","key":"i1551-6776-25-6-476-b12","series-title":"J Infect Chemother","first-page":"154","article-title":"Assessment of optimal initial dosing regimen with vancomycin pharmacokinetics model in very low birth weight neonates","volume":"23","year":"2017","unstructured":"Kato\n              H\n            , HagiharaM, NishiyamaN, \n          et al. Assessment of optimal initial dosing regimen with vancomycin pharmacokinetics model in very low birth weight neonates. J Infect Chemother. 2017;23(3):154\u2013160."},{"key":"i1551-6776-25-6-476-b13","series-title":"Pharmacol Res","doi-asserted-by":"publisher","first-page":"104278","DOI":"10.1016\/j.phrs.2019.104278","article-title":"Optimisation of vancomycin exposure in neonates based on the best level of evidence","volume":"154","year":"2020","unstructured":"Dao\n              K\n            , GuidiM, PadreP, \n          et al. Optimisation of vancomycin exposure in neonates based on the best level of evidence. Pharmacol Res. 2020;154:104278. doi:10.1016\/j.phrs.2019.104278"},{"issue":"2","key":"i1551-6776-25-6-476-b14","series-title":"J Pediatric Infect Dis Soc","first-page":"97","article-title":"Individualized empiric vancomycin dosing in neonates using a model-based approach","volume":"8","year":"2019","unstructured":"Frymoyer\n              A\n            , StockmannC, HershAL, \n          et al. Individualized empiric vancomycin dosing in neonates using a model-based approach. J Pediatric Infect Dis Soc. 2019;8(2):97\u2013104."},{"issue":"11","key":"i1551-6776-25-6-476-b15","series-title":"Antimicrob Agents Chemother","first-page":"6454","article-title":"Association between vancomycin trough concentration and area under the concentration-time curve in neonates","volume":"58","year":"2014","unstructured":"Frymoyer\n              A\n            , HershAL, El-KomyMH, \n          et al. Association between vancomycin trough concentration and area under the concentration-time curve in neonates. Antimicrob Agents Chemother. 2014;58(11):6454\u20136461."},{"issue":"2","key":"i1551-6776-25-6-476-b16","series-title":"Infect Dis Ther","first-page":"187","article-title":"Predictive performance of a vancomycin population pharmacokinetic model in neonates","volume":"4","year":"2015","unstructured":"Stockmann\n              C\n            , HershAL, RobertsJK, \n          et al. Predictive performance of a vancomycin population pharmacokinetic model in neonates. Infect Dis Ther. 2015;4(2):187\u2013198."},{"issue":"suppl 1","key":"i1551-6776-25-6-476-b17","series-title":"Clin Infect Dis","first-page":"S35","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","year":"2006","unstructured":"Rybak\n              MJ.\n            \n          \n          The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42(suppl 1):S35\u2013S39."},{"issue":"2","key":"i1551-6776-25-6-476-b18","series-title":"Infect Dis Clin North Am","first-page":"479","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid","volume":"17","year":"2003","unstructured":"Craig\n              WA.\n            \n          \n          Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am. 2003;17(2):479\u2013501."},{"issue":"1","key":"i1551-6776-25-6-476-b19","series-title":"Am J Health Syst Pharm","first-page":"82","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","year":"2009","unstructured":"Rybak\n              M\n            , LomaestroB, RotschaferJC, \n          et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82\u201398."},{"issue":"3","key":"i1551-6776-25-6-476-b20","series-title":"Clin Infect Dis","first-page":"285","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","year":"2011","unstructured":"Liu\n              C\n            , BayerA, CosgroveSE, \n          et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285\u2013292."},{"issue":"5","key":"i1551-6776-25-6-476-b21","series-title":"J Pediatr","first-page":"1193","article-title":"Neonatal sepsis 2004\u20132013: the rise and fall of coagulase-negative staphylococci","volume":"166","year":"2015","unstructured":"Bizzarro\n              M\n            , ShabanovaV, BaltimoreR, \n          et al. Neonatal sepsis 2004\u20132013: the rise and fall of coagulase-negative staphylococci. J Pediatr. 2015;166(5):1193\u20131199."},{"issue":"3","key":"i1551-6776-25-6-476-b22","series-title":"J Pediatr Infect Dis Soc","first-page":"259","article-title":"Vancomycin dosing practices, trough concentrations, and predicted area under the curve in children with suspected invasive staphylococcal infections","volume":"2","year":"2013","unstructured":"Chhim\n              RF\n            , ArnoldSR, LeeKR.\n          Vancomycin dosing practices, trough concentrations, and predicted area under the curve in children with suspected invasive staphylococcal infections. J Pediatr Infect Dis Soc. 2013;2(3):259\u2013262."},{"issue":"12","key":"i1551-6776-25-6-476-b23","series-title":"J Clin Microbiol","first-page":"4652","article-title":"Vancomycin MIC for methicillin-resistant coagulase-negative Staphylococcus isolates: evaluation of the broth microdilution and Etest methods","volume":"48","year":"2010","unstructured":"Paiva\n              RM\n            , MombachAB, MachadoP, \n          et al. Vancomycin MIC for methicillin-resistant coagulase-negative Staphylococcus isolates: evaluation of the broth microdilution and Etest methods. J Clin Microbiol. 2010;48(12):4652\u20134654."},{"issue":"1","key":"i1551-6776-25-6-476-b24","series-title":"BMC Pediatr.","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12887-016-0753-0","article-title":"Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?","volume":"16","year":"2016","unstructured":"Padari\n              H\n            , OselinK, TasaT, \n          et al. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?BMC Pediatr.2016;16(1):206. doi: 10.1186\/s12887-016-0753-0."},{"key":"i1551-6776-25-6-476-b25","series-title":"Neofax 2010, A Manual of Drugs Used in Neonatal Care","year":"2010","unstructured":"Young\n              TE\n            , MagnumB.\n          Neofax 2010, A Manual of Drugs Used in Neonatal Care. 23rd ed. Thomas Reuters Clinical Editorial; 2010."},{"issue":"7","key":"i1551-6776-25-6-476-b26","series-title":"Eur J Clin Pharmacol","first-page":"921","article-title":"Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants","volume":"74","year":"2018","unstructured":"Chen\n              Y\n            , WuD, DongM, \n          Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants. Eur J Clin Pharmacol. 2018;74(7):921\u2013930."},{"issue":"4","key":"i1551-6776-25-6-476-b27","series-title":"Antimicrob Agent Chemother","first-page":"e01647","article-title":"Evaluating the relationship between vancomycin trough concentration and 24-hour area under the concentration-time curve in neonates","volume":"62","year":"2018","unstructured":"Tseng\n              SH\n            , LimCP, ChenQ, \n          et al. Evaluating the relationship between vancomycin trough concentration and 24-hour area under the concentration-time curve in neonates. Antimicrob Agent Chemother. 2018;62(4):e01647\u2013617."},{"key":"i1551-6776-25-6-476-b28","series-title":"BMC Pediatrics","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12887-017-0777-0","article-title":"The association between vancomycin trough concentrations and acute kidney injury in the neonatal intensive care unit","volume":"17","year":"2017","unstructured":"Bhargava\n              V\n            , MalloyM, FonsecaR.\n          The association between vancomycin trough concentrations and acute kidney injury in the neonatal intensive care unit. BMC Pediatrics. 2017;17:50. doi:10.1186\/s12887-017-0777-0"},{"issue":"11","key":"i1551-6776-25-6-476-b29","series-title":"Am J Health Syst Pharm","first-page":"835","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists","volume":"77","year":"2020","unstructured":"Rybak\n              MJ\n            , LeJ, LodiseTP, \n          et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835\u2013864"},{"issue":"3","key":"i1551-6776-25-6-476-b30","series-title":"Curr Opin Infect Dis","first-page":"237","article-title":"Vancomycin toxicity in neonates: a review of the evidence","volume":"29","year":"2016","unstructured":"Lestner\n              JM\n            , HillLF, HeathPT, SharlandM.\n          Vancomycin toxicity in neonates: a review of the evidence. Curr Opin Infect Dis. 2016;29(3):237\u2013247."},{"issue":"1","key":"i1551-6776-25-6-476-b31","series-title":"Br J Clin Pharmacol","first-page":"2436","article-title":"An evaluation of the user-friendliness of Bayesian forecasting programs in a clinical setting","volume":"85","year":"2019","unstructured":"Kumar\n              AA\n            , BurgardM, StaceyS, \n          et al. An evaluation of the user-friendliness of Bayesian forecasting programs in a clinical setting. Br J Clin Pharmacol. 2019;85(1):2436\u20132441."},{"issue":"7","key":"i1551-6776-25-6-476-b32","series-title":"J Clin Microbiol","first-page":"2077","article-title":"Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods","volume":"51","year":"2013","unstructured":"Rybak\n              MJ\n            , VidaillacC, SaderHS, \n          et al. Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods. J Clin Microbiol. 2013;51(7):2077\u20132081."},{"issue":"6","key":"i1551-6776-25-6-476-b33","series-title":"J Clin Microbiol","first-page":"2272","article-title":"Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus","volume":"49","year":"2011","unstructured":"Kruzel\n              MC\n            , LewisCT, WelshKJ, \n          et al. Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2011;49(6):2272\u20132273."},{"issue":"1","key":"i1551-6776-25-6-476-b34","series-title":"Trials","first-page":"329:2","article-title":"NeoVanc Consortium. An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset bacterial sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial","volume":"21","year":"2020","unstructured":"Hill\n              LF\n            , TurnerMA, LutsarI, \n          et al. NeoVanc Consortium. An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset bacterial sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial. Trials2020;21(1):329:2\u201311."},{"issue":"2","key":"i1551-6776-25-6-476-b35","series-title":"Antimicrob Agents Chemother","first-page":"1013","article-title":"Towards rational dosing algorithms for vancomycin in neonates and infants based on population pharmacokinetic modeling","volume":"60","year":"2016","unstructured":"Janssen\n              EJH\n            , ValitaloPAJ, AllegaertK, \n          et al. Towards rational dosing algorithms for vancomycin in neonates and infants based on population pharmacokinetic modeling. Antimicrob Agents Chemother. 2016;60(2):1013\u20131021."},{"key":"i1551-6776-25-6-476-b36","series-title":"Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life","article-title":"Vancomycin","year":"2015","unstructured":"Vancomycin. In: Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life. 7th ed. West Sussex, United Kingdom: John Wiley & Sons, Ltd; 2015."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/25\/6\/article-p476.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/25\/6\/476\/2585563\/1551-6776-25_6_476.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/25\/6\/article-p476.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/25\/6\/article-p476.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:38:59Z","timestamp":1747355939000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/25\/6\/article-p476.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":36,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-25.6.476","relation":{},"ISSN":["1551-6776"],"issn-type":[{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}